|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC25A4 |
Gene summary for SLC25A4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC25A4 | Gene ID | 291 |
| Gene name | solute carrier family 25 member 4 | |
| Gene Alias | AAC1 | |
| Cytomap | 4q35.1 | |
| Gene Type | protein-coding | GO ID | GO:0000002 | UniProtAcc | A0A0S2Z3H3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 291 | SLC25A4 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.04e-12 | 3.77e-01 | -0.1954 |
| 291 | SLC25A4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.16e-02 | 2.12e-01 | -0.059 |
| 291 | SLC25A4 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.27e-11 | 3.83e-01 | 0.294 |
| 291 | SLC25A4 | LZE4T | Human | Esophagus | ESCC | 1.03e-10 | 3.89e-01 | 0.0811 |
| 291 | SLC25A4 | LZE5T | Human | Esophagus | ESCC | 1.93e-06 | 2.91e-01 | 0.0514 |
| 291 | SLC25A4 | LZE7T | Human | Esophagus | ESCC | 8.49e-08 | 8.72e-01 | 0.0667 |
| 291 | SLC25A4 | LZE8T | Human | Esophagus | ESCC | 4.96e-08 | 2.37e-01 | 0.067 |
| 291 | SLC25A4 | LZE20T | Human | Esophagus | ESCC | 1.00e-02 | 3.15e-01 | 0.0662 |
| 291 | SLC25A4 | LZE22T | Human | Esophagus | ESCC | 4.55e-03 | 2.66e-01 | 0.068 |
| 291 | SLC25A4 | LZE24T | Human | Esophagus | ESCC | 2.29e-14 | 5.20e-01 | 0.0596 |
| 291 | SLC25A4 | LZE21T | Human | Esophagus | ESCC | 8.70e-05 | 2.38e-01 | 0.0655 |
| 291 | SLC25A4 | LZE6T | Human | Esophagus | ESCC | 1.94e-02 | 1.47e-01 | 0.0845 |
| 291 | SLC25A4 | P1T-E | Human | Esophagus | ESCC | 3.32e-08 | 3.30e-01 | 0.0875 |
| 291 | SLC25A4 | P2T-E | Human | Esophagus | ESCC | 8.57e-37 | 7.52e-01 | 0.1177 |
| 291 | SLC25A4 | P4T-E | Human | Esophagus | ESCC | 6.58e-34 | 9.10e-01 | 0.1323 |
| 291 | SLC25A4 | P5T-E | Human | Esophagus | ESCC | 3.58e-42 | 8.49e-01 | 0.1327 |
| 291 | SLC25A4 | P8T-E | Human | Esophagus | ESCC | 3.04e-37 | 6.67e-01 | 0.0889 |
| 291 | SLC25A4 | P9T-E | Human | Esophagus | ESCC | 6.04e-22 | 4.63e-01 | 0.1131 |
| 291 | SLC25A4 | P10T-E | Human | Esophagus | ESCC | 5.83e-40 | 7.17e-01 | 0.116 |
| 291 | SLC25A4 | P11T-E | Human | Esophagus | ESCC | 3.78e-12 | 5.03e-01 | 0.1426 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00973002 | Esophagus | ESCC | programmed necrotic cell death | 32/8552 | 47/18723 | 1.59e-03 | 7.43e-03 | 32 |
| GO:00702654 | Esophagus | ESCC | necrotic cell death | 39/8552 | 62/18723 | 4.68e-03 | 1.82e-02 | 39 |
| GO:00002662 | Esophagus | ESCC | mitochondrial fission | 28/8552 | 42/18723 | 4.90e-03 | 1.89e-02 | 28 |
| GO:190260018 | Esophagus | ESCC | proton transmembrane transport | 88/8552 | 157/18723 | 5.62e-03 | 2.10e-02 | 88 |
| GO:19035999 | Esophagus | ESCC | positive regulation of autophagy of mitochondrion | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
| GO:000609112 | Liver | Cirrhotic | generation of precursor metabolites and energy | 238/4634 | 490/18723 | 6.85e-31 | 1.07e-27 | 238 |
| GO:000989612 | Liver | Cirrhotic | positive regulation of catabolic process | 215/4634 | 492/18723 | 1.13e-20 | 3.56e-18 | 215 |
| GO:003133112 | Liver | Cirrhotic | positive regulation of cellular catabolic process | 190/4634 | 427/18723 | 1.94e-19 | 4.18e-17 | 190 |
| GO:00224117 | Liver | Cirrhotic | cellular component disassembly | 182/4634 | 443/18723 | 1.59e-14 | 1.54e-12 | 182 |
| GO:001623611 | Liver | Cirrhotic | macroautophagy | 129/4634 | 291/18723 | 1.75e-13 | 1.41e-11 | 129 |
| GO:00068397 | Liver | Cirrhotic | mitochondrial transport | 112/4634 | 254/18723 | 1.03e-11 | 6.66e-10 | 112 |
| GO:001050611 | Liver | Cirrhotic | regulation of autophagy | 132/4634 | 317/18723 | 2.17e-11 | 1.33e-09 | 132 |
| GO:19030084 | Liver | Cirrhotic | organelle disassembly | 59/4634 | 114/18723 | 4.82e-10 | 2.27e-08 | 59 |
| GO:00070065 | Liver | Cirrhotic | mitochondrial membrane organization | 57/4634 | 116/18723 | 1.13e-08 | 4.29e-07 | 57 |
| GO:00004225 | Liver | Cirrhotic | autophagy of mitochondrion | 43/4634 | 81/18723 | 4.02e-08 | 1.31e-06 | 43 |
| GO:00617265 | Liver | Cirrhotic | mitochondrion disassembly | 43/4634 | 81/18723 | 4.02e-08 | 1.31e-06 | 43 |
| GO:00108216 | Liver | Cirrhotic | regulation of mitochondrion organization | 62/4634 | 144/18723 | 1.09e-06 | 2.22e-05 | 62 |
| GO:00159316 | Liver | Cirrhotic | nucleobase-containing compound transport | 87/4634 | 222/18723 | 1.25e-06 | 2.52e-05 | 87 |
| GO:00162414 | Liver | Cirrhotic | regulation of macroautophagy | 60/4634 | 141/18723 | 2.57e-06 | 4.63e-05 | 60 |
| GO:00086377 | Liver | Cirrhotic | apoptotic mitochondrial changes | 47/4634 | 107/18723 | 1.10e-05 | 1.57e-04 | 47 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05012 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
| hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
| hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
| hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa05016 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
| hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa05017 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
| hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
| hsa04218 | Colorectum | AD | Cellular senescence | 53/2092 | 156/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 53 |
| hsa050121 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
| hsa052081 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
| hsa054151 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
| hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa050161 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa050201 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
| hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa050171 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
| hsa051661 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
| hsa042181 | Colorectum | AD | Cellular senescence | 53/2092 | 156/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 53 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC25A4 | SNV | Missense_Mutation | novel | c.367N>A | p.Ala123Thr | p.A123T | P12235 | protein_coding | tolerated(0.06) | possibly_damaging(0.801) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC25A4 | SNV | Missense_Mutation | c.238N>T | p.Arg80Cys | p.R80C | P12235 | protein_coding | deleterious(0.01) | possibly_damaging(0.645) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC25A4 | SNV | Missense_Mutation | c.166N>C | p.Asp56His | p.D56H | P12235 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SLC25A4 | SNV | Missense_Mutation | novel | c.657N>G | p.Ser219Arg | p.S219R | P12235 | protein_coding | tolerated(0.13) | benign(0.109) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| SLC25A4 | SNV | Missense_Mutation | c.344N>A | p.Gly115Asp | p.G115D | P12235 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-AD-6888-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
| SLC25A4 | SNV | Missense_Mutation | c.455N>A | p.Arg152His | p.R152H | P12235 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| SLC25A4 | SNV | Missense_Mutation | rs748031233 | c.670N>A | p.Ala224Thr | p.A224T | P12235 | protein_coding | deleterious(0) | possibly_damaging(0.869) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC25A4 | SNV | Missense_Mutation | c.740N>T | p.Ala247Val | p.A247V | P12235 | protein_coding | deleterious(0.04) | benign(0.013) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SLC25A4 | SNV | Missense_Mutation | c.848G>A | p.Gly283Asp | p.G283D | P12235 | protein_coding | deleterious(0.02) | possibly_damaging(0.899) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC25A4 | SNV | Missense_Mutation | novel | c.703C>T | p.Arg235Cys | p.R235C | P12235 | protein_coding | tolerated(0.06) | possibly_damaging(0.554) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 291 | SLC25A4 | DRUGGABLE GENOME, TRANSPORTER | Clodronate | CLODRONIC ACID | ||
| 291 | SLC25A4 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | 178101293 | ||
| 291 | SLC25A4 | DRUGGABLE GENOME, TRANSPORTER | CLODRONATE | CLODRONIC ACID | ||
| 291 | SLC25A4 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | 53801038 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |